香港作为国际金融中心，正为各地企业提供多元的融资渠道。据统计，截至2025年6月30日，在港上市 的医疗保健行业总市值为4410亿美元(占香港上市公司市值总值约8.1%)，是2017年底1440亿美元的3 倍。值得一提的是，截至今年年中已有73家按照18A制度上市的生物科技公司，总共融资160亿美元。 香港贸发局研究副总监(代理)赵永础认为，香港不仅提供金融资源，还利用其技术优势，帮助合作企业 开拓内地及海外市场，其中香港先进的临床试验能力，以及取得的临床试验数据均获国际认可，使香港 成为拓展全球生物医药业务的理想地点。 香港贸易发展局(以下简称"香港贸发局")发布《粤港澳大湾区科技创新合作：香港伙同内地推进生物医 药产业升级发展》研究报告显示，香港正与广东及澳门协同推进大湾区科技创新合作，当中生物医药已 成为大湾区创新科技集群中的重要产业。 报告显示，香港生物医药产业已形成具规模的企业集群，其中2023年在港相关企业达3020家，相对2013 年的2340家显著增加。在此良好势头之上，广东省政府锐意进一步推动生物医药产业快速集聚发展趋 势，今年初出台《广东省加快建设生物制造产业创新高地行动方案》，旨在加快推 ...

Group 1 - The "Shenzhen-Hong Kong-Guangzhou" innovation cluster ranks first in the 2025 Global Innovation Index, surpassing the "Tokyo-Yokohama" cluster which held the top position for five consecutive years [1] - The "Shenzhen-Hong Kong-Guangzhou" cluster is ranked 45th in innovation intensity, while the "Macau-Zhuhai" cluster, which debuted in 2024, has risen to 98th place and is ranked 81st in innovation intensity [1] - The Greater Bay Area's innovation landscape is characterized by the active collaboration between the Guangzhou-Shenzhen-Hong Kong and Guangzhou-Zhuhai-Macau corridors, with the latter becoming a hub for technology cooperation [1] Group 2 - A number of innovation platforms are emerging along the Guangzhou-Zhuhai-Macau corridor, including the China-Portuguese-speaking Countries Technology Exchange and Cooperation Center in Macau and the Zhuhai-Hengqin Center, both of which are fully operational [2] - The Guangdong-Hong Kong-Macau Greater Bay Area Development Plan emphasizes the construction of an international technology innovation center, aiming to deepen innovation cooperation and create a collaborative innovation community [2] - The plan focuses on gathering international innovation resources, optimizing the innovation policy environment, and enhancing the ability to transform scientific and technological achievements into practical applications [2]